ACTUALLY - the trials were only labeled as "signal seeking" AFTER they were started and AFTER Garnick came on the scene and probably reviewed the design and errors, and named them signal seeking. Remember when we were all surprised with the signal seeking verbiage after the fact? Were you around then? Inept management. And as mojo says - no reason to compare the results with Avastin - trial design is apples to oranges. Hopefully things will be different with the Phase 2b. If results are good, though there's an issue with trial design or patient demographics or anything else that precludes it from getting compared to the SOC, the dream is over.
Market Data 
Markets 
AI
